SlideShare a Scribd company logo
1 of 29
Affinity Team Intern
June- August
Impossible Foods
By Kristin Cook
Who Am I
 2nd
Year Doctor of Pharmacy Candidate
Florida Agricultural and Mechanical University
Tallahassee, FL
LIFE GOALS
 Clinical Trials Pharmacist
 Pharmacogenomics- studies the relationship
between a drugs pharmacologic response to a
patients genetic makeup
 Assist with Drug Safety, Efficacy, Reduction and
Resolution of Adverse Drug Reactions
Kristin + Affinity Team
 Perfect Fit!
 Laila and Wayne focus on the discovery and
small scale synthesis of Ligands attached to
DNA, and measuring their binding affinities.
 Bobby synthesizes the specific Ligands on a
large scale to confirm binding and prepare
protein affinity resins.
Kristin + Affinity Team cont.
affinity – natural liking or relationship
Critical Thinking
Problem Solving
Organic Synthesis
 What kinds of functional groups
are tolerated in the synthesis?
 What is the range of different
structures that can be used?
Color coding process
 4 pieces, represent structures added at the same step in the sequence
 Reagents for each step differ
Structure of each compound was confirmed by liquid
chromatography/mass spectrometry (LC/MS)
 Purity of compounds is assessed by UV/Vis HPLC and
LC/MS
 Mass spectrum is compared against theoretical spectrum to
identify products
 NMR is the preferred method for measuring purity, but we
were dealing with insufficient quantities for NMR analysis
Scope of ligand synthesis
Ligands that Bind to
Bovine Carbonic Anhydrase (BCA)
Sulfonamides are
known to bind
to BCA
Ligands that Bind to
Bovine Carbonic Anhydrase (BCA)
cont.
Synthesis Scheme
KC-5A ResultsZ:Bobby160623160623_HN_KC5_A 06/23/16 14:12:08
RT: 0.00 - 10.01
0 1 2 3 4 5 6 7 8 9 10
Time (min)
0
10
20
30
40
50
60
70
80
90
100
RelativeAbundance
RT: 4.57
BP: 604.18
8.69
291.20
4.88
364.12 7.58
321.17 8.73
291.20
3.96
705.25
7.02
277.18
0.36
315.07 5.43
770.29
3.73
221.00 8.98
197.81
2.70
197.81
NL:
3.07E9
TIC F: FTMS - p
ESI Full ms
[120.00-
1800.00] MS
160623_HN_KC
5_A
600 605 610 615
m/z
0
20
40
60
80
100
0
20
40
60
80
100
RelativeAbundance
604.1753
z=1
606.1719
z=1
607.1748
z=1 610.1737
z=?
604.1740
606.1710
607.1744
610.1735 613.1811
NL:
6.68E8
160623_HN_KC5_A#4
62 RT: 4.57 AV: 1 T:
FTMS - p ESI Full ms
[120.00-1800.00]
NL:
5.20E5
C26 H31 ClN7 O6 S:
C26 H31 Cl1 N7 O 6 S 1
pa Chrg 1
Expected MW: 706.78
Observed MW: 604.17
Z:Bobby160623160623_HN_KC5_C 06/23/16 14:34:30
RT: 0.00 - 10.02
0 1 2 3 4 5 6 7 8 9 10
Time (min)
0
10
20
30
40
50
60
70
80
90
100
RelativeAbundance
RT: 4.86
MA: 28327227634
BP: 640.15
RT: 4.01
MA: 33969591437
BP: 698.23
7.60
282.28
5.17
400.09
7.48
256.26 8.64
531.41
0.33
130.16
3.11
454.12 5.66
806.26
3.05
454.12
2.22
156.06
8.78
214.09
NL:
9.49E9
TIC F: FTMS +
p ESI Full ms
[120.00-
1800.00] MS
160623_HN_KC
5_C
660 680 700 720 740
m/z
0
20
40
60
80
100
0
20
40
60
80
100
RelativeAbundance
698.2274
z=1
701.2269
z=1
714.2211
z=1
752.1477
z=1
657.2813
z=?
734.5754
z=?
698.2271
706.2309
NL:
1.46E9
160623_HN_KC5_C#4
07 RT: 4.02 AV: 1 T:
FTMS + p ESI Full ms
[120.00-1800.00]
NL:
4.89E5
C31 H37 ClN9 O 6 S:
C31 H37 Cl1 N9 O 6 S 1
pa Chrg 1
50%
KC-5C Results
Decreased conversion
may be due to the
presence of the
aromatic ring in the
D or purple synthon.
Z:Bobby160623160623_HN_KC5_C 06/23/16 14:34:30
RT: 0.00 - 10.02
0 1 2 3 4 5 6 7 8 9 10
Time (min)
0
10
20
30
40
50
60
70
80
90
100
RelativeAbundance
RT: 4.86
MA: 28327227634
BP: 640.15
RT: 4.01
MA: 33969591437
BP: 698.23
7.60
282.28
5.17
400.09
7.48
256.26 8.64
531.41
0.33
130.16
3.11
454.12 5.66
806.26
3.05
454.12
2.22
156.06
8.78
214.09
NL:
9.49E9
TIC F: FTMS +
p ESI Full ms
[120.00-
1800.00] MS
160623_HN_KC
5_C
635 640 645 650 655
m/z
0
20
40
60
80
100
0
20
40
60
80
100
RelativeAbundance
640.1513
z=1
642.1484
z=1
643.1505
z=1
646.1465
z=1
640.1506
642.1477
643.1510
645.1481 648.1472 651.1548
NL:
3.68E9
160623_HN_KC5_C#4
93 RT: 4.86 AV: 1 T:
FTMS + p ESI Full ms
[120.00-1800.00]
NL:
3.94E5
C26 H32 Cl2 N7 O 6 S:
C26 H32 Cl2 N7 O 6 S1
pa Chrg 1
KC-5C Results
50%
Unsuccessful Reactions
A synthon possibly caused resin
decomposition.
Unsuccessful Reactions
Z:Bobby160623160623_HN_KC5_F 06/23/16 15:08:03
RT: 0.00 - 10.02
0 1 2 3 4 5 6 7 8 9 10
Time (min)
0
10
20
30
40
50
60
70
80
90
100
RelativeAbundance
RT: 4.37
MA: 17465119957
BP: 857.09
0.33
201.07 7.59
282.28
4.37
857.09
4.41
857.09 8.65
531.417.47
256.26
0.45
201.07
3.35
530.08
6.13
296.262.84
346.03 8.81
214.09
NL:
1.29E10
TIC F: FTMS +
p ESI Full ms
[120.00-
1800.00] MS
160623_HN_KC
5_F
878 880 882 884 886 888
m/z
0
20
40
60
80
0
20
40
60
80
RelativeAbundance
880.1945
z=1878.1964
z=?
881.1966
z=1
879.1991
z=1
882.1946
z=1 884.1948
z=1
878.1960 880.1939
879.1993 881.1973
882.1897
884.1964 886.1922 888.1965
NL:
1.70E9
160623_HN_KC5_F#4
07 RT: 4.04 AV: 1 T:
FTMS + p ESI Full ms
[120.00-1800.00]
NL:
2.95E5
C35 H45 BrN9 O9 S2:
C35 H45 Br1 N9 O9 S2
pa Chrg 1
successful Reactions
Full Conversion
Z:Bobby160623160623_HN_KC5_G 06/23/16 15:19:13
RT: 0.00 - 10.01
0 1 2 3 4 5 6 7 8 9 10
Time (min)
0
10
20
30
40
50
60
70
80
90
100
RelativeAbundance
RT: 4.63
MA: 2492301925
BP: 604.18
8.69
291.20
7.59
321.17
4.06
747.29
3.88
637.23
7.01
277.18
8.77
291.20
0.34
418.14
2.93
418.14 6.37
305.225.94
291.20 8.89
197.812.82
418.141.38
236.09
NL:
1.41E9
TIC F: FTMS - p
ESI Full ms
[120.00-
1800.00] MS
160623_HN_KC
5_G
596 598 600 602 604 606 608 610
m/z
0
20
40
60
80
100
0
20
40
60
80
100
RelativeAbundance
604.1756
z=1
606.1726
z=1
607.1750
z=1 609.1699
z=1
601.9421
z=?
603.6881
z=?
604.1740
606.1710
607.1744
609.1702
NL:
3.35E8
160623_HN_KC5_G#4
68 RT: 4.65 AV: 1 T:
FTMS - p ESI Full ms
[120.00-1800.00]
NL:
5.20E5
C26 H31 ClN7 O6 S:
C26 H31 Cl1 N7 O6 S1
pa Chrg 1
Unsuccessful Reaction
Possible Solution?
Carboxylic Acid
Possible Solution?
Methyl Ester
Alkene Metathesis
 New chemistry for making the library
 Library consists of macrocycles synthesized by ring-closing
metathesis (RCM)
 8-membered rings through 13-member rings are strained (9 has the
highest, 13 kcal/mol)
 14-membered rings and greater have little to no strain (e.g. 15-
member ring has 1.5 kcal/mol strain)
Alkene Metathesis RXN
Ring-closing Metathesis (RCM) RXN
Catalyst
Catalyst
13-Membered Ring RCM
Synthesis of A Glycinate
Z:Bobby160715160715_HN_RVO_RC_09 07/15/16 10:02:43
RT: 0.00 - 10.02
0 1 2 3 4 5 6 7 8 9 10
Time (min)
0
10
20
30
40
50
60
70
80
90
100
RT:2.24
BP:130.09
7.57
282.28
NL:
1.19E10
TIC F: FTMS + p
ESI Full ms
[120.00-1800.00]
MS
160715_HN_RVO
_RC_09
50
100
150
200
186.1488
z=1
187.1520
z=1
188.1526
z=?
189.1557
z=?
185.0233
z=?
NL:
1.98E8
160715_HN_RVO_R
C_09#233 RT: 2.30
AV: 1 T: FTMS + p
ESI Full ms
[120.00-1800.00]
0 1 2 3 4 5 6 7 8 9 10
Time (min)
0
10
20
30
40
50
60
70
80
90
100
RelativeAbundance
RT:2.24
BP:130.09
7.57
282.2
TIC F: FTMS + p
ESI Full ms
[120.00-1800.00]
MS
160715_HN_RVO
_RC_09
185 186 187 188 189 190 191 192
m/z
0
50
100
150
200
0
50
100
150
200
RelativeAbundance
186.1488
z=1
187.1520
z=1
188.1526
z=?
189.1557
z=?
185.0233
z=?
186.1489
187.1522
188.1556 189.1565 190.1598
NL:
1.98E8
160715_HN_RVO_R
C_09#233 RT: 2.30
AV: 1 T: FTMS + p
ESI Full ms
[120.00-1800.00]
NL:
8.88E5
C10 H20 NO2:
C10 H20 N1 O2
pa Chrg 1
Z:Bobby160715160715_HN_RVO_10 07/15/16 10:14:06
RT: 0.00 - 10.02
0 1 2 3 4 5 6 7 8 9 10
Time (min)
0
10
20
30
40
50
60
70
80
90
100
RelativeAbundance
RT:7.01
BP:282.21
7.58
282.28
NL:
2.06E10
TIC F: FTMS + p
ESI Full ms
[120.00-
1800.00] MS
160715_HN_RV
O_10
280 300 320 340 360
m/z
0
20
40
60
80
100
0
20
40
60
80
100
RelativeAbundance
282.2061
z=1
338.2685
z=1
360.2503
z=1
304.1878
z=1
285.2136
z=? 341.2771
z=?
338.2690
344.2866
NL:
8.34E9
160715_HN_RVO_1
0#717 RT: 7.01
AV: 1 T: FTMS + p
ESI Full ms
[120.00-1800.00]
NL:
7.94E5
C20 H36 NO3:
C20 H36 N1 O3
pa Chrg 1
Bobby160715160715_HN_RVO_10 07/15/16 10:14:06
RT: 0.00 - 10.02
0 1 2 3 4 5 6 7 8 9 10
Time (min)
0
10
20
30
40
50
60
70
80
90
100
RT:7.01
BP:282.21
7.58
282.28
NL:
2.06E10
TIC F: FTMS + p
ESI Full ms
[120.00-
1800.00] MS
160715_HN_RV
O_10
80
100
282.2061
z=1
NL:
8.34E9
160715_HN_RVO_1
0#717 RT: 7.01
Acylation
Z:Bobby160715160715_HN_RVO_KC_11 07/15/16 10:25:28
RT: 0.00 - 10.01
0 1 2 3 4 5 6 7 8 9 10
Time (min)
0
20
40
60
80
100
RelativeAbundance
RT:7.00
MA:31329293598
BP:282.21
RT:6.29
MA:22127653815
BP:254.17
7.58
282.28
8.13
647.50
NL:
1.61E10
TIC F: FTMS + p
ESI Full ms
[120.00-1800.00]
MS
160715_HN_RVO
_KC_11
200 250 300 350
m/z
0
20
40
60
80
100
0
20
40
60
80
100
RelativeAbundance
254.1747
z=1
226.1799
z=1
310.2371
z=1
335.2786
z=1
284.1852
z=1
196.1694
z=1
362.2295
z=?
310.2377
NL:
1.71E9
160715_HN_RVO_K
C_11#647 RT: 6.29
AV: 1 T: FTMS + p
ESI Full ms
[120.00-1800.00]
NL:
8.12E5
C18 H32 NO3:
C18 H32 N1 O3
pa Chrg 1
Z:Bobby160715160715_HN_RVO_KC_11 07/15/16 10:25:28
RT: 0.00 - 10.01
0 1 2 3 4 5 6 7 8 9 10
Time (min)
0
20
40
60
80
100
RT:7.00
MA:31329293598
BP:282.21
RT:6.29
MA:22127653815
BP:254.17
7.58
282.28
8.13
647.50
NL:
1.61E10
TIC F: FTMS + p
ESI Full ms
[120.00-1800.00]
MS
160715_HN_RVO
_KC_11
100
254.1747
z=1
NL:
1.71E9
Alkene Metathesis
Hoveyda Grubbs Second Generation Catalyst
~40% conversion
13-membered ring 5 kcal/mol ring strain decreased the conversion rate
SEPARATING ALKENES BY silver nitrate silica
Silver Nitrate silica allows separation of alkenes that are
inseparable by regular silica chromatography
Silver Nitrate non covalently binds to alkenes
Since the starting material contains two alkenes it should
move slower up the plate in comparison to the final product,
which has one alkene.
LC/MS Data For Metathesis RXN
A very friendly environment
Witnessing the companies progression
The Affinity Team was very encouraging
 Unique and genuine personalities collaborated on
several levels
What I Liked Best About Working Here
There is a place for everybody at Impossible Foods
 Degrees and Work Experiences vary extensively, and
Impossible is home to all.
What I found most interesting
Acknowledgements
Patrick Brown
Chris Davis
Bobby O’Brien
Laila Dafik
Wayne Hsieh
Amy Lie
Siatta Adams
Puja Agrawal
Harshada Natekar
Alex Shulman
Oliver Zahn
Everyone else at Impossible
Foods!

More Related Content

Similar to Pres IF2

3 hou jian
3 hou jian3 hou jian
3 hou jianspa718
 
Nucleoside libray e-conference VRX-Harry
Nucleoside libray e-conference VRX-HarryNucleoside libray e-conference VRX-Harry
Nucleoside libray e-conference VRX-HarryHarry An
 
Antiretroviral Therapy Update 2016
Antiretroviral Therapy Update 2016Antiretroviral Therapy Update 2016
Antiretroviral Therapy Update 2016hivlifeinfo
 
Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...
Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...
Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...Egyptian National Cancer Institute
 
Levels and fate of antimycotic pharmaceuticals at sewage treatment plants
Levels and fate of antimycotic pharmaceuticals at sewage treatment plantsLevels and fate of antimycotic pharmaceuticals at sewage treatment plants
Levels and fate of antimycotic pharmaceuticals at sewage treatment plantsJorge Casado Agrelo
 
Native and IM-MS characterization of ADCs
Native and IM-MS characterization of ADCsNative and IM-MS characterization of ADCs
Native and IM-MS characterization of ADCsWaters Corporation
 
ASMS 2014 poster final
ASMS 2014 poster finalASMS 2014 poster final
ASMS 2014 poster finalNathan Bond
 
Non–Small Cell Lung Cancer
Non–Small Cell Lung CancerNon–Small Cell Lung Cancer
Non–Small Cell Lung Cancerfondas vakalis
 
Quality evaluation of melon cubes preserved in sweeteners solutions
Quality evaluation of melon cubes preserved in sweeteners solutionsQuality evaluation of melon cubes preserved in sweeteners solutions
Quality evaluation of melon cubes preserved in sweeteners solutionsAhmad Salarzai
 
Rutger Ploeg - The Netherlands - Tuesday 29 - Use of Perfusion Machines or ...
Rutger Ploeg  - The Netherlands  - Tuesday 29 - Use of Perfusion Machines or ...Rutger Ploeg  - The Netherlands  - Tuesday 29 - Use of Perfusion Machines or ...
Rutger Ploeg - The Netherlands - Tuesday 29 - Use of Perfusion Machines or ...incucai_isodp
 
leaders_5y_presentation
leaders_5y_presentationleaders_5y_presentation
leaders_5y_presentationiveccc
 
MLSC-382A INSTRUCTOR BETH RAWSON 1 Resu
MLSC-382A       INSTRUCTOR BETH RAWSON     1 ResuMLSC-382A       INSTRUCTOR BETH RAWSON     1 Resu
MLSC-382A INSTRUCTOR BETH RAWSON 1 ResuIlonaThornburg83
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivetsOleg Kshivets
 
S4.3. Association Mapping, Breeder Ready markers and Genomic Selection
S4.3. Association Mapping, Breeder Ready markers and Genomic SelectionS4.3. Association Mapping, Breeder Ready markers and Genomic Selection
S4.3. Association Mapping, Breeder Ready markers and Genomic SelectionCIMMYT
 
Incyte INCB39110 study results
Incyte INCB39110 study resultsIncyte INCB39110 study results
Incyte INCB39110 study resultsinnovaderm
 
EDSP webinar 2: In vitro assays for the EDSP
EDSP webinar 2: In vitro assays for the EDSPEDSP webinar 2: In vitro assays for the EDSP
EDSP webinar 2: In vitro assays for the EDSPJim Regan
 
ARM 2008: Dissection, characterisation and utilisation of disease QTL -- R Ne...
ARM 2008: Dissection, characterisation and utilisation of disease QTL -- R Ne...ARM 2008: Dissection, characterisation and utilisation of disease QTL -- R Ne...
ARM 2008: Dissection, characterisation and utilisation of disease QTL -- R Ne...CGIAR Generation Challenge Programme
 

Similar to Pres IF2 (20)

3 hou jian
3 hou jian3 hou jian
3 hou jian
 
Nucleoside libray e-conference VRX-Harry
Nucleoside libray e-conference VRX-HarryNucleoside libray e-conference VRX-Harry
Nucleoside libray e-conference VRX-Harry
 
Antiretroviral Therapy Update 2016
Antiretroviral Therapy Update 2016Antiretroviral Therapy Update 2016
Antiretroviral Therapy Update 2016
 
Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...
Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...
Locally advanced Rectal cancer debate: adjuvant chemotherapy following neoadj...
 
Levels and fate of antimycotic pharmaceuticals at sewage treatment plants
Levels and fate of antimycotic pharmaceuticals at sewage treatment plantsLevels and fate of antimycotic pharmaceuticals at sewage treatment plants
Levels and fate of antimycotic pharmaceuticals at sewage treatment plants
 
Native and IM-MS characterization of ADCs
Native and IM-MS characterization of ADCsNative and IM-MS characterization of ADCs
Native and IM-MS characterization of ADCs
 
Investigating Fruit Juice Authenticity using MS - Waters Corporation Food Res...
Investigating Fruit Juice Authenticity using MS - Waters Corporation Food Res...Investigating Fruit Juice Authenticity using MS - Waters Corporation Food Res...
Investigating Fruit Juice Authenticity using MS - Waters Corporation Food Res...
 
ASMS 2014 poster final
ASMS 2014 poster finalASMS 2014 poster final
ASMS 2014 poster final
 
Non–Small Cell Lung Cancer
Non–Small Cell Lung CancerNon–Small Cell Lung Cancer
Non–Small Cell Lung Cancer
 
Quality evaluation of melon cubes preserved in sweeteners solutions
Quality evaluation of melon cubes preserved in sweeteners solutionsQuality evaluation of melon cubes preserved in sweeteners solutions
Quality evaluation of melon cubes preserved in sweeteners solutions
 
RNA (gene expression) analysis of Prostate cancers and non-cancerous tissues t
RNA (gene expression) analysis of Prostate cancers and non-cancerous tissues tRNA (gene expression) analysis of Prostate cancers and non-cancerous tissues t
RNA (gene expression) analysis of Prostate cancers and non-cancerous tissues t
 
Rutger Ploeg - The Netherlands - Tuesday 29 - Use of Perfusion Machines or ...
Rutger Ploeg  - The Netherlands  - Tuesday 29 - Use of Perfusion Machines or ...Rutger Ploeg  - The Netherlands  - Tuesday 29 - Use of Perfusion Machines or ...
Rutger Ploeg - The Netherlands - Tuesday 29 - Use of Perfusion Machines or ...
 
MCC 2011 - Slide 16
MCC 2011 - Slide 16MCC 2011 - Slide 16
MCC 2011 - Slide 16
 
leaders_5y_presentation
leaders_5y_presentationleaders_5y_presentation
leaders_5y_presentation
 
MLSC-382A INSTRUCTOR BETH RAWSON 1 Resu
MLSC-382A       INSTRUCTOR BETH RAWSON     1 ResuMLSC-382A       INSTRUCTOR BETH RAWSON     1 Resu
MLSC-382A INSTRUCTOR BETH RAWSON 1 Resu
 
2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets2021 esmo world_gi_poster_kshivets
2021 esmo world_gi_poster_kshivets
 
S4.3. Association Mapping, Breeder Ready markers and Genomic Selection
S4.3. Association Mapping, Breeder Ready markers and Genomic SelectionS4.3. Association Mapping, Breeder Ready markers and Genomic Selection
S4.3. Association Mapping, Breeder Ready markers and Genomic Selection
 
Incyte INCB39110 study results
Incyte INCB39110 study resultsIncyte INCB39110 study results
Incyte INCB39110 study results
 
EDSP webinar 2: In vitro assays for the EDSP
EDSP webinar 2: In vitro assays for the EDSPEDSP webinar 2: In vitro assays for the EDSP
EDSP webinar 2: In vitro assays for the EDSP
 
ARM 2008: Dissection, characterisation and utilisation of disease QTL -- R Ne...
ARM 2008: Dissection, characterisation and utilisation of disease QTL -- R Ne...ARM 2008: Dissection, characterisation and utilisation of disease QTL -- R Ne...
ARM 2008: Dissection, characterisation and utilisation of disease QTL -- R Ne...
 

Pres IF2

  • 1. Affinity Team Intern June- August Impossible Foods By Kristin Cook
  • 2. Who Am I  2nd Year Doctor of Pharmacy Candidate Florida Agricultural and Mechanical University Tallahassee, FL
  • 3. LIFE GOALS  Clinical Trials Pharmacist  Pharmacogenomics- studies the relationship between a drugs pharmacologic response to a patients genetic makeup  Assist with Drug Safety, Efficacy, Reduction and Resolution of Adverse Drug Reactions
  • 4. Kristin + Affinity Team  Perfect Fit!  Laila and Wayne focus on the discovery and small scale synthesis of Ligands attached to DNA, and measuring their binding affinities.  Bobby synthesizes the specific Ligands on a large scale to confirm binding and prepare protein affinity resins.
  • 5. Kristin + Affinity Team cont. affinity – natural liking or relationship Critical Thinking Problem Solving
  • 6. Organic Synthesis  What kinds of functional groups are tolerated in the synthesis?  What is the range of different structures that can be used?
  • 7. Color coding process  4 pieces, represent structures added at the same step in the sequence  Reagents for each step differ Structure of each compound was confirmed by liquid chromatography/mass spectrometry (LC/MS)  Purity of compounds is assessed by UV/Vis HPLC and LC/MS  Mass spectrum is compared against theoretical spectrum to identify products  NMR is the preferred method for measuring purity, but we were dealing with insufficient quantities for NMR analysis Scope of ligand synthesis
  • 8. Ligands that Bind to Bovine Carbonic Anhydrase (BCA) Sulfonamides are known to bind to BCA
  • 9. Ligands that Bind to Bovine Carbonic Anhydrase (BCA) cont.
  • 11. KC-5A ResultsZ:Bobby160623160623_HN_KC5_A 06/23/16 14:12:08 RT: 0.00 - 10.01 0 1 2 3 4 5 6 7 8 9 10 Time (min) 0 10 20 30 40 50 60 70 80 90 100 RelativeAbundance RT: 4.57 BP: 604.18 8.69 291.20 4.88 364.12 7.58 321.17 8.73 291.20 3.96 705.25 7.02 277.18 0.36 315.07 5.43 770.29 3.73 221.00 8.98 197.81 2.70 197.81 NL: 3.07E9 TIC F: FTMS - p ESI Full ms [120.00- 1800.00] MS 160623_HN_KC 5_A 600 605 610 615 m/z 0 20 40 60 80 100 0 20 40 60 80 100 RelativeAbundance 604.1753 z=1 606.1719 z=1 607.1748 z=1 610.1737 z=? 604.1740 606.1710 607.1744 610.1735 613.1811 NL: 6.68E8 160623_HN_KC5_A#4 62 RT: 4.57 AV: 1 T: FTMS - p ESI Full ms [120.00-1800.00] NL: 5.20E5 C26 H31 ClN7 O6 S: C26 H31 Cl1 N7 O 6 S 1 pa Chrg 1 Expected MW: 706.78 Observed MW: 604.17
  • 12. Z:Bobby160623160623_HN_KC5_C 06/23/16 14:34:30 RT: 0.00 - 10.02 0 1 2 3 4 5 6 7 8 9 10 Time (min) 0 10 20 30 40 50 60 70 80 90 100 RelativeAbundance RT: 4.86 MA: 28327227634 BP: 640.15 RT: 4.01 MA: 33969591437 BP: 698.23 7.60 282.28 5.17 400.09 7.48 256.26 8.64 531.41 0.33 130.16 3.11 454.12 5.66 806.26 3.05 454.12 2.22 156.06 8.78 214.09 NL: 9.49E9 TIC F: FTMS + p ESI Full ms [120.00- 1800.00] MS 160623_HN_KC 5_C 660 680 700 720 740 m/z 0 20 40 60 80 100 0 20 40 60 80 100 RelativeAbundance 698.2274 z=1 701.2269 z=1 714.2211 z=1 752.1477 z=1 657.2813 z=? 734.5754 z=? 698.2271 706.2309 NL: 1.46E9 160623_HN_KC5_C#4 07 RT: 4.02 AV: 1 T: FTMS + p ESI Full ms [120.00-1800.00] NL: 4.89E5 C31 H37 ClN9 O 6 S: C31 H37 Cl1 N9 O 6 S 1 pa Chrg 1 50% KC-5C Results Decreased conversion may be due to the presence of the aromatic ring in the D or purple synthon.
  • 13. Z:Bobby160623160623_HN_KC5_C 06/23/16 14:34:30 RT: 0.00 - 10.02 0 1 2 3 4 5 6 7 8 9 10 Time (min) 0 10 20 30 40 50 60 70 80 90 100 RelativeAbundance RT: 4.86 MA: 28327227634 BP: 640.15 RT: 4.01 MA: 33969591437 BP: 698.23 7.60 282.28 5.17 400.09 7.48 256.26 8.64 531.41 0.33 130.16 3.11 454.12 5.66 806.26 3.05 454.12 2.22 156.06 8.78 214.09 NL: 9.49E9 TIC F: FTMS + p ESI Full ms [120.00- 1800.00] MS 160623_HN_KC 5_C 635 640 645 650 655 m/z 0 20 40 60 80 100 0 20 40 60 80 100 RelativeAbundance 640.1513 z=1 642.1484 z=1 643.1505 z=1 646.1465 z=1 640.1506 642.1477 643.1510 645.1481 648.1472 651.1548 NL: 3.68E9 160623_HN_KC5_C#4 93 RT: 4.86 AV: 1 T: FTMS + p ESI Full ms [120.00-1800.00] NL: 3.94E5 C26 H32 Cl2 N7 O 6 S: C26 H32 Cl2 N7 O 6 S1 pa Chrg 1 KC-5C Results 50%
  • 14. Unsuccessful Reactions A synthon possibly caused resin decomposition.
  • 16. Z:Bobby160623160623_HN_KC5_F 06/23/16 15:08:03 RT: 0.00 - 10.02 0 1 2 3 4 5 6 7 8 9 10 Time (min) 0 10 20 30 40 50 60 70 80 90 100 RelativeAbundance RT: 4.37 MA: 17465119957 BP: 857.09 0.33 201.07 7.59 282.28 4.37 857.09 4.41 857.09 8.65 531.417.47 256.26 0.45 201.07 3.35 530.08 6.13 296.262.84 346.03 8.81 214.09 NL: 1.29E10 TIC F: FTMS + p ESI Full ms [120.00- 1800.00] MS 160623_HN_KC 5_F 878 880 882 884 886 888 m/z 0 20 40 60 80 0 20 40 60 80 RelativeAbundance 880.1945 z=1878.1964 z=? 881.1966 z=1 879.1991 z=1 882.1946 z=1 884.1948 z=1 878.1960 880.1939 879.1993 881.1973 882.1897 884.1964 886.1922 888.1965 NL: 1.70E9 160623_HN_KC5_F#4 07 RT: 4.04 AV: 1 T: FTMS + p ESI Full ms [120.00-1800.00] NL: 2.95E5 C35 H45 BrN9 O9 S2: C35 H45 Br1 N9 O9 S2 pa Chrg 1 successful Reactions Full Conversion
  • 17. Z:Bobby160623160623_HN_KC5_G 06/23/16 15:19:13 RT: 0.00 - 10.01 0 1 2 3 4 5 6 7 8 9 10 Time (min) 0 10 20 30 40 50 60 70 80 90 100 RelativeAbundance RT: 4.63 MA: 2492301925 BP: 604.18 8.69 291.20 7.59 321.17 4.06 747.29 3.88 637.23 7.01 277.18 8.77 291.20 0.34 418.14 2.93 418.14 6.37 305.225.94 291.20 8.89 197.812.82 418.141.38 236.09 NL: 1.41E9 TIC F: FTMS - p ESI Full ms [120.00- 1800.00] MS 160623_HN_KC 5_G 596 598 600 602 604 606 608 610 m/z 0 20 40 60 80 100 0 20 40 60 80 100 RelativeAbundance 604.1756 z=1 606.1726 z=1 607.1750 z=1 609.1699 z=1 601.9421 z=? 603.6881 z=? 604.1740 606.1710 607.1744 609.1702 NL: 3.35E8 160623_HN_KC5_G#4 68 RT: 4.65 AV: 1 T: FTMS - p ESI Full ms [120.00-1800.00] NL: 5.20E5 C26 H31 ClN7 O6 S: C26 H31 Cl1 N7 O6 S1 pa Chrg 1 Unsuccessful Reaction
  • 20. Alkene Metathesis  New chemistry for making the library  Library consists of macrocycles synthesized by ring-closing metathesis (RCM)  8-membered rings through 13-member rings are strained (9 has the highest, 13 kcal/mol)  14-membered rings and greater have little to no strain (e.g. 15- member ring has 1.5 kcal/mol strain) Alkene Metathesis RXN Ring-closing Metathesis (RCM) RXN Catalyst Catalyst
  • 22. Synthesis of A Glycinate Z:Bobby160715160715_HN_RVO_RC_09 07/15/16 10:02:43 RT: 0.00 - 10.02 0 1 2 3 4 5 6 7 8 9 10 Time (min) 0 10 20 30 40 50 60 70 80 90 100 RT:2.24 BP:130.09 7.57 282.28 NL: 1.19E10 TIC F: FTMS + p ESI Full ms [120.00-1800.00] MS 160715_HN_RVO _RC_09 50 100 150 200 186.1488 z=1 187.1520 z=1 188.1526 z=? 189.1557 z=? 185.0233 z=? NL: 1.98E8 160715_HN_RVO_R C_09#233 RT: 2.30 AV: 1 T: FTMS + p ESI Full ms [120.00-1800.00] 0 1 2 3 4 5 6 7 8 9 10 Time (min) 0 10 20 30 40 50 60 70 80 90 100 RelativeAbundance RT:2.24 BP:130.09 7.57 282.2 TIC F: FTMS + p ESI Full ms [120.00-1800.00] MS 160715_HN_RVO _RC_09 185 186 187 188 189 190 191 192 m/z 0 50 100 150 200 0 50 100 150 200 RelativeAbundance 186.1488 z=1 187.1520 z=1 188.1526 z=? 189.1557 z=? 185.0233 z=? 186.1489 187.1522 188.1556 189.1565 190.1598 NL: 1.98E8 160715_HN_RVO_R C_09#233 RT: 2.30 AV: 1 T: FTMS + p ESI Full ms [120.00-1800.00] NL: 8.88E5 C10 H20 NO2: C10 H20 N1 O2 pa Chrg 1
  • 23. Z:Bobby160715160715_HN_RVO_10 07/15/16 10:14:06 RT: 0.00 - 10.02 0 1 2 3 4 5 6 7 8 9 10 Time (min) 0 10 20 30 40 50 60 70 80 90 100 RelativeAbundance RT:7.01 BP:282.21 7.58 282.28 NL: 2.06E10 TIC F: FTMS + p ESI Full ms [120.00- 1800.00] MS 160715_HN_RV O_10 280 300 320 340 360 m/z 0 20 40 60 80 100 0 20 40 60 80 100 RelativeAbundance 282.2061 z=1 338.2685 z=1 360.2503 z=1 304.1878 z=1 285.2136 z=? 341.2771 z=? 338.2690 344.2866 NL: 8.34E9 160715_HN_RVO_1 0#717 RT: 7.01 AV: 1 T: FTMS + p ESI Full ms [120.00-1800.00] NL: 7.94E5 C20 H36 NO3: C20 H36 N1 O3 pa Chrg 1 Bobby160715160715_HN_RVO_10 07/15/16 10:14:06 RT: 0.00 - 10.02 0 1 2 3 4 5 6 7 8 9 10 Time (min) 0 10 20 30 40 50 60 70 80 90 100 RT:7.01 BP:282.21 7.58 282.28 NL: 2.06E10 TIC F: FTMS + p ESI Full ms [120.00- 1800.00] MS 160715_HN_RV O_10 80 100 282.2061 z=1 NL: 8.34E9 160715_HN_RVO_1 0#717 RT: 7.01 Acylation
  • 24. Z:Bobby160715160715_HN_RVO_KC_11 07/15/16 10:25:28 RT: 0.00 - 10.01 0 1 2 3 4 5 6 7 8 9 10 Time (min) 0 20 40 60 80 100 RelativeAbundance RT:7.00 MA:31329293598 BP:282.21 RT:6.29 MA:22127653815 BP:254.17 7.58 282.28 8.13 647.50 NL: 1.61E10 TIC F: FTMS + p ESI Full ms [120.00-1800.00] MS 160715_HN_RVO _KC_11 200 250 300 350 m/z 0 20 40 60 80 100 0 20 40 60 80 100 RelativeAbundance 254.1747 z=1 226.1799 z=1 310.2371 z=1 335.2786 z=1 284.1852 z=1 196.1694 z=1 362.2295 z=? 310.2377 NL: 1.71E9 160715_HN_RVO_K C_11#647 RT: 6.29 AV: 1 T: FTMS + p ESI Full ms [120.00-1800.00] NL: 8.12E5 C18 H32 NO3: C18 H32 N1 O3 pa Chrg 1 Z:Bobby160715160715_HN_RVO_KC_11 07/15/16 10:25:28 RT: 0.00 - 10.01 0 1 2 3 4 5 6 7 8 9 10 Time (min) 0 20 40 60 80 100 RT:7.00 MA:31329293598 BP:282.21 RT:6.29 MA:22127653815 BP:254.17 7.58 282.28 8.13 647.50 NL: 1.61E10 TIC F: FTMS + p ESI Full ms [120.00-1800.00] MS 160715_HN_RVO _KC_11 100 254.1747 z=1 NL: 1.71E9 Alkene Metathesis Hoveyda Grubbs Second Generation Catalyst ~40% conversion 13-membered ring 5 kcal/mol ring strain decreased the conversion rate
  • 25. SEPARATING ALKENES BY silver nitrate silica Silver Nitrate silica allows separation of alkenes that are inseparable by regular silica chromatography Silver Nitrate non covalently binds to alkenes Since the starting material contains two alkenes it should move slower up the plate in comparison to the final product, which has one alkene.
  • 26. LC/MS Data For Metathesis RXN
  • 27. A very friendly environment Witnessing the companies progression The Affinity Team was very encouraging  Unique and genuine personalities collaborated on several levels What I Liked Best About Working Here
  • 28. There is a place for everybody at Impossible Foods  Degrees and Work Experiences vary extensively, and Impossible is home to all. What I found most interesting
  • 29. Acknowledgements Patrick Brown Chris Davis Bobby O’Brien Laila Dafik Wayne Hsieh Amy Lie Siatta Adams Puja Agrawal Harshada Natekar Alex Shulman Oliver Zahn Everyone else at Impossible Foods!

Editor's Notes

  1. 7 structures were chosen from a list that met the criteria of
  2. Acylation, Amination, Addition
  3. Add desired MW
  4. Aromatic Ring- decreased the likelihood of going all the way to the product because of the other resonance structures
  5. full ligand missing possibly because of solid support resin decomposition… there was immediate discoloration when the resin was added; with all of the other compounds this was not observed
  6. Full conversion
  7. Steps A, B, and C worked but step D didn’t Carboxylic acid containing amines did notdissolve well with THF; possibly a solubility problem not reactivity
  8. Convert to a Methylester
  9. PHD
  10. PHD